BioSpace News Archive

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has entered into an agreement to sell Series A Convertible preferred stock, convertible into 4,388,852 shares of common stock, to an investment fund affiliated with RA Capital Management (RA Capital) in a private placement, at an effective purchase price per share of common stock equal

International Isotopes Inc. (OTCQB: INIS) (the “Company”) is pleased to announce it has hired Dr. James R. Miles, PharmD., ANP as its new Radiopharmaceutical Production Manager.

Amabiotics Inc., a global biotech company developing disease-modifying therapies for neurological conditions, announced today that it is changing its corporate name to Stellate Therapeutics Inc. (Stellate). This new name reflects the company’s strategic focus of using the human gut-brain axis to change the trajectory of brain di

Encompass Health Corp. announces the opening of Encompass Health Rehabilitation Hospital of Sioux Falls, the Company’s first inpatient rehabilitation hospital in South Dakota.

Therap Services, national leader in HIPAA-compliant web-based documentation, reporting, communication and electronic billing solutions for Medicaid-funded Home and Community Based Services (HCBS) and broader Long Term Services and Supports (LTSS

oday BioRender, creator of the first web-based graphical tool for scientists to create publication and presentation-ready figures, announced its inaugural Graphical Abstract Contest, to give scientists a way to promote their research and win prize rewards.

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is pleased to announce that on Saturday, June 27, 2020, Dr. Marco Valgimigli, MD, PhD, Professor of Cardiology, Director of Clinical Research at Bern University Hospital, will present the results of the FABOLUS-FASTER Phase 4 clinical trial.

Shown to improve attention function, EndeavorRx is backed by data from five clinical studies, including a prospective, randomized controlled trial

Lantern Pharma Inc. announced the closing of its initial public offering of 1,750,000 shares of its common stock at a public offering price of $15.00 per share, for gross proceeds of $26,250,000, before deducting underwriting discounts, commissions and offering expenses.

In the TV series Westworld, human body parts are built on robotic frames using 3D printers.